drugset / Trial / NCT01257048

Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler

NCT01257048

Phase 0 Completed 34 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to evaluate the sensitivity of a new oxygen enhanced magnetic resonance imaging (OE-MRI) method in detecting changes in the lungs of patients with moderate to severe chronic obstructive pulmonary disease (COPD) following treatment with either Oxis Turbuhaler or Symbicort Turbuhaler.

Timeline

Start
2011-08
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 320 ug
Comparator Formoterol Other / unclassified 9 ug